KB-1282

Ponsegromab

52692

Home » Ponsegromab

Background of Ponsegromab

Ponsegromab (formerly PF 06946860) is a subcutaneously administered, growth differentiation factor 15 (GDF15) inhibitor, being developed by Pfizer, for the treatment of cachexia. This is a secondary reaction, mainly caused by tumor cell products and cytokines released by the body, and manifests as loss of appetite, weight loss, anemia, weakness, exhaustion, etc. About 20% of cancer patients die from cancer cachexia.

Specifications

Catalog Number	KB-1282
Antibody Name	Ponsegromab
Isotype	Human IgG1,kappa
FC Muations	L234A/L235A/G237A/K447Del
Target	GDF15
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Lyall, D. M. et al. Association of body mass index with cardiometabolic disease in the UK Biobank: a Mendelian randomization study. JAMA Cardiol. 2, 882–889 (2017).
Fabbrini, E., Sullivan, S. & Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679–689 (2010).
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908–922 (2018).